Mylan Pharmaceuticals (Nasdaq: MYL) has won a potential $121.5 million contract from the Defense Logistics Agency to provide lidocaine 5 percent patch, a medicine designed for the treatment of post-herpetic neuralgia pain.
Mylan will supply the medical product to the departments of Defense and Veterans Affairs as well as the Indian Health Services and Federal Bureau of Prisons under the firm-fixed-price contract, DoD said Tuesday.
DoD noted the contract has one base year and four option years.
The company will perform work in West Virginia, Vermont and North Carolina through Sept. 12, 2021.
DLA Troop Support received four proposals for the contract and will obligate defense working capital funds in fiscal year 2017 through fiscal 2021.